18,796 trials (keyword fallback)
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Primary: Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration — 75.0; 33.3 percentage of patients
Kawasaki Disease
Primary: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion — 11; 11…
Mucocutaneous Lymph Node Syndrome
Primary: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. — 25; 40 Participants
Kawasaki Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Obsessive-Compulsive Disorder · Children · Anxiety Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale Total Score — 20.59; 25.67 units on a scale — p=0.44
Kawasaki Disease
Primary: Number of Participants With Adverse Events — 2; 3; 13 participants
Kawasaki Disease
Primary: Number of Participants With SAE — 4 Participants
Hyperbilirubinemia · Erythroblastosis, Fetal
Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765
Kawasaki Disease
Primary: Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) — 2; 3 events
Kawasaki Disease
Primary: Determine the Predictive Value of Cardiolite® Rest and Stress MPI to Define Pediatric Populations With Kawasaki Disease at High and Low Risk of Developing Cardiac…
Mucocutaneous Lymph Node Syndrome · Kawasaki Disease
Primary: IVIG Refractory — 13; 22 Participants — p=.10
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
Perioral Rhytids · Aging · Wrinkle
Primary: Change From Baseline in Perioral Rhytids Severity Rating Scale (PR-SRS) Score Rated by the Blinded Live Evaluator (BLE) at Week 8 After Last Treatment. — 121; 4; 29; 47…
Hypogammaglobulinemia · Lung Transplantation
Primary: Number of Clinically Diagnosed Bacterial Infections During the Treatment Period — 3; 1 Infections
Mild Cognitive Impairment
Primary: Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI — 5.87; 8.14; 6.26; 7.08 percent change per participant year